Upgrade to SI Premium - Free Trial

Anthem (ANTM) Tops Q4 EPS by 25c, Miss on Revenues; Offers FY19 EPS/Revenue Guidance Above Consensus

January 30, 2019 6:02 AM

Anthem (NYSE: ANTM) reported Q4 EPS of $2.44, $0.25 better than the analyst estimate of $2.19. Revenue for the quarter came in at $23.373 billion versus the consensus estimate of $23.38 billion.

"In 2018, we achieved our objectives of improving execution and strengthening our value proposition with innovative and affordable solutions designed to more effectively meet the unique needs of our customers," said Gail K. Boudreaux, President and CEO. "Our fourth quarter and full year performance provides a strong foundation for 2019. In addition, I am pleased to announce that we are accelerating the launch of IngenioRx and now expect to begin transitioning members in the second quarter of this year. Since announcing our intent to create IngenioRx, we have been carefully planning the transition, including the possibility of an early launch, and are confident in our ability to execute the transition under the accelerated schedule. This will allow us to go to market with better economics earlier, and also accelerate our whole person health strategy, which is proven to reduce total cost of care."


Anthem sees FY2019 EPS of $19.00, versus the consensus of $17.61. Anthem sees FY2019 revenue of $100 billion, versus the consensus of $97.67 billion.

Full Year 2019:

For earnings history and earnings-related data on Anthem (ANTM) click here.


Corporate News Earnings Guidance Hot Guidance Management Comments

Next Articles